Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 3, 2009, Pages 673-679

  Belozeroff, Vasily ^a   Goodman, William G ^a   Ren, Lulu ^a   Kalantar Zadeh, Kamyar ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D STEROL; NAPHTHALENE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; POST HOC ANALYSIS; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; ADULT; AGED; AUSTRALIA; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; EUROPE; FEMALE; KIDNEY DISEASE; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ALKALINE PHOSPHATASE; AUSTRALIA; CALCIUM; DOUBLE-BLIND METHOD; DOWN-REGULATION; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 66149102049     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03790808     Document Type: Article

References (33)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
2. Goodman WG, Quarles LD: Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 74: 276-288, 2008
3. Raggi P: Cardiovascular calcification in end stage renal disease. Contrib Nephrol 149: 272-278, 2005 (Pubitemid 43265023)
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001 (Pubitemid 34258697)
5. Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2: 1241-1248, 2007
6. Hruska KA, Saab G, Mathew S, Lund R: Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 20: 309-315, 2007
7. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 17: 2094-2105, 2002 (Pubitemid 35416745)
8. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 (Pubitemid 39031360)
9. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005 (Pubitemid 41623345)
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006 (Pubitemid 44215354)
11. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19: 2193-2203, 2008
12. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, Akiba T, Keen ML, Young EW, Port FK: High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74: 655-663, 2008
13. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004 (Pubitemid 38477776)
14. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005 (Pubitemid 41725117)
15. Sterrett JR, Strom J, Sturmvoll H-K, Bahner U, Disney A, Soroka SD, Corpier C, Arruda JA, Schwanauer LE, Klassen PE, Olson KA, Block GA: Cinacalcet HCl (Sensipar®/Mimpara®) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68: 10-17, 2007 (Pubitemid 47045487)
16. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793 - 1800, 2005
17. Jean G, Chazot C, Charra B: 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 68: 63-64, 2007 (Pubitemid 47045498)
18. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635, 2004 (Pubitemid 38134225)
19. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 333: 166-174, 1995
20. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A: Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99: 2961-2970, 1997 (Pubitemid 27278673)
21. Taal MW, Masud T, Green D, Cassidy MJ: Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 14: 1922-1928, 1999
22. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7: 506-512, 1996 (Pubitemid 26128321)
23. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC: Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 73: 1024-1030, 2008 (Pubitemid 351543906)
24. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC: Phosphate-induced vascular calcification: Role of pyrophosphate and osteopontin. J Am Soc Nephrol 15: 1392-1401, 2004 (Pubitemid 38679664)
25. Locatelli F, Cannata-Andia JB, Drueke TB, Horl WH, Fouque D, Heimberger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant 17: 723-731, 2002 (Pubitemid 34521119)
26. Chang W, Tu C, Chen TH, Komuves L, Oda Y, Pratt SA, Miller S, Shoback D: Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140: 5883-5893, 1999 (Pubitemid 30645377)
27. Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D: Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci U S A 101: 5140-5145, 2004 (Pubitemid 38469215)
28. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47: 149-156, 2006 (Pubitemid 41828277)
29. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003 (Pubitemid 37098542)
30. Davies MR, Lund RJ, Mathew S, Hruska KA: Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16: 917-928, 2005 (Pubitemid 41710302)
31. Raymond NT, Zehnder D, Smith SC, Stinson JA, Lehnert H, Higgins RM: Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age. Nephrol Dial Transplant 22: 3214-3220, 2007 (Pubitemid 350202561)
32. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005 (Pubitemid 41710323)
33. Zhang J, Yu KF: What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280: 1690-1691, 1998 (Pubitemid 28532993)